

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	918	(546/112,514/299).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/08/29 08:06
L2	83	I1 and imidazol	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/08/29 08:07
L3	0	I2 and acetylcholin	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/08/29 08:07

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAY 01	New CAS web site launched
NEWS	3	MAY 08	CA/CAPplus Indian patent publication number format defined
NEWS	4	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	5	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	6	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	7	MAY 21	CA/CAPplus enhanced with additional kind codes for German patents
NEWS	8	MAY 22	CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS	9	JUN 27	CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS	10	JUN 29	STN Viewer now available
NEWS	11	JUN 29	STN Express, Version 8.2, now available
NEWS	12	JUL 02	LEMBASE coverage updated
NEWS	13	JUL 02	LMEDLINE coverage updated
NEWS	14	JUL 02	SCISEARCH enhanced with complete author names
NEWS	15	JUL 02	CHEMCATS accession numbers revised
NEWS	16	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS	17	JUL 16	CAPplus enhanced with French and German abstracts
NEWS	18	JUL 18	CA/CAPplus patent coverage enhanced
NEWS	19	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	20	JUL 30	USGENE now available on STN
NEWS	21	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	22	AUG 06	BEILSTEIN updated with new compounds
NEWS	23	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	24	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	25	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	26	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	27	AUG 27	USPATOLD now available on STN
NEWS	28	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:57:00 ON 29 AUG 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'REGISTRY' ENTERED AT 07:57:56 ON 29 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 AUG 2007 HIGHEST RN 945714-55-6

DICTIONARY FILE UPDATES: 28 AUG 2007 HIGHEST RN 945714-55-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10579609.str



chain nodes :

5 6 7 8 18 19 20 22 23

ring nodes :

1 2 3 4 9 10 11 12 13 14 15 16 21

chain bonds :

1-6 1-5 2-20 3-12 4-8 4-7 13-19 16-18 21-22 21-23

ring bonds :

1-2 1-21 2-3 2-11 3-4 4-9 9-21 9-10 10-11 12-13 12-16 13-14 14-15 15-16

exact/norm bonds :

1-2 1-21 2-3 2-11 3-4 3-12 4-9 9-21 9-10 10-11 12-13 12-16 13-14 14-15

exact bonds :

1-6 1-5 2-20 4-8 4-7 13-19 15-16 16-18 21-22 21-23
 isolated ring systems :
 containing 12 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:Atom 10:Atom
 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:CLASS 19:CLASS 20:CLASS
 21:Atom 22:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS


L1 STR



Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10579609a.str



chain nodes :

5 6 7 8 17 18 19 21 22

ring nodes :

1 2 3 4 9 10 11 12 13 14 15 20

chain bonds :

1-6 1-5 2-19 3-11 4-8 4-7 12-18 15-17 20-21 20-22

ring bonds :

1-2 1-20 2-3 2-10 3-4 4-9 9-20 9-10 11-12 11-15 12-13 13-14 14-15

exact/norm bonds :

1-2 1-20 2-3 2-10 3-4 3-11 4-9 9-20 9-10 11-12 11-15 12-13 13-14

exact bonds :

1-6 1-5 2-19 4-8 4-7 12-18 14-15 15-17 20-21 20-22

isolated ring systems :
containing 11 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:CLASS 18:CLASS 19:CLASS 20:Atom
21:CLASS 22:CLASS

L2 STRUCTURE UPLOADED

=> d 12

L2 HAS NO ANSWERS


L2 STR



Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\10579609b.str



chain nodes :

5 6 7 8 16 17 18 20 21

ring nodes :

1 2 3 4 9 10 11 12 13 14 19 22

chain bonds :

1-6 1-5 2-18 3-10 4-8 4-7 11-17 14-16 19-21 19-20

ring bonds :

1-2 1-19 2-3 2-9 3-4 4-22 9-22 10-11 10-14 11-12 12-13 13-14 19-22

exact/norm bonds :

1-2 1-19 2-3 2-9 3-4 3-10 4-22 9-22 10-11 10-14 11-12 12-13 19-22

exact bonds :

1-6 1-5 2-18 4-8 4-7 11-17 13-14 14-16 19-21 19-20

isolated ring systems :
containing 10 :


Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 16:CLASS 17:CLASS 18:CLASS 19:Atom
20:CLASS 21:CLASS 22:Atom

L3 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10579609c.str



chain nodes :

6 7 8 9 19 20 21 22

ring nodes :

1 2 3 4 5 10 11 12 13 14 15 16 17

chain bonds :

2-6 2-7 3-21 4-13 5-9 5-8 10-22 14-20 17-19

ring bonds :

1-10 1-2 2-3 3-4 3-12 4-5 5-10 10-11 11-12 13-14 13-17 14-15 15-16
16-17

exact/norm bonds :

1-10 1-2 2-3 3-4 3-12 4-5 4-13 5-10 10-11 11-12 13-14 13-17 14-15
15-16

exact bonds :

2-6 2-7 3-21 5-9 5-8 10-22 14-20 16-17 17-19

isolated ring systems :

containing 1 : 13 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:CLASS 20:CLASS
21:CLASS 22:CLASS

L4 STRUCTURE UPLOADED

=> d 12


L2 HAS NO ANSWERS

L2 STR




Structure attributes must be viewed using STN Express query preparation.

=> d 13
 L3 HAS NO ANSWERS
 L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> d 14
 L4 HAS NO ANSWERS
 L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 08:00:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 324 TO ITERATE

100.0% PROCESSED 324 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

L5 13 SEA SSS FUL L1

=> s l2 full

FULL SEARCH INITIATED 08:00:15 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 162 TO ITERATE

100.0% PROCESSED 162 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L6 0 SEA SSS FUL L2

=> s l3 full

FULL SEARCH INITIATED 08:00:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 2812 TO ITERATE

100.0% PROCESSED 2812 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L7 0 SEA SSS FUL L3

=> s l4 full

FULL SEARCH INITIATED 08:00:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 51722 TO ITERATE

100.0% PROCESSED 51722 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L8 0 SEA SSS FUL L4

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

688.40

688.82

FILE 'CAPLUS' ENTERED AT 08:00:29 ON 29 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Aug 2007 VOL 147 ISS 10
FILE LAST UPDATED: 28 Aug 2007 (20070828/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s 15 full
L9 2 L5

=> d ibib abs hitstr tot

L9 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:472155 CAPLUS
DOCUMENT NUMBER: 143:7863
TITLE: Preparation of 1-(azabicyclyl)-4-substituted-imidazoles for use in pharmaceutical compositions as $\alpha 4$ and $\alpha 7$ nicotinic acetylcholine receptor (nAChR) agonists
INVENTOR(S): Empfield, James; Phillips, Eifion; Throner, Scott
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049612	A1	20050602	WO 2004-SE1660	20041115
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004291457	A1	20050602	AU 2004-291457	20041115
CA 2546096	A1	20050602	CA 2004-2546096	20041115
EP 1687303	A1	20060809	EP 2004-800323	20041115
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS			
CN 1882584	A	20061220	CN 2004-80034245	20041115
BR 2004016629	A	20070116	BR 2004-16629	20041115

JP 2007511603	T	20070510	JP 2006-541086	20041115
IN 2006DN02411	A	20070420	IN 2006-DN2411	20060501
MX 2006PA05416	A	20060719	MX 2006-PA5416	20060512
US 2007105896	A1	20070510	US 2006-579609	20060517
NO 2006002862	A	20060821	NO 2006-2862	20060619
PRIORITY APPLN. INFO.:			SE 2003-3075	A 20031119
			WO 2004-SE1660	W 20041115
OTHER SOURCE(S):	CASREACT 143:7863; MARPAT 143:7863			
GI				




AB Azabicyclic-midazole derivs., such as I [A = azabicyclic, such as 3-quinuclidinyl, or 1-azabicyclo[2.2.1]heptan-3-yl; R1 = aryl, heteroaryl], were prepared for therapeutic use as $\alpha 4$ and $\alpha 7$ nAChR agonists. These imidazoles are claimed for use in the treatment of ulcerative colitis, as well as for use in the treatment or prophylaxis of neurol. disorders, psychotic disorders or intellectual impairment disorders, such as Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapses, jetlag, nicotine addiction, craving, pain, anxiety, schizophrenia, mania or manic depression. Thus, (R)-3-(4-phenylimidazol-1-yl)-1-azabicyclo[2.2.2]octane (II) was prepared with 41% yield by cyclization of phenylglyoxal hydrate with (R)-(+)-3-aminoquinuclidine dihydrochloride, ammonium acetate and formaldehyde in AcOH. The prepared imidazoles were assayed for binding affinity to the $\alpha 4$ and $\alpha 7$ nAChR subtypes using rat hippocampi.

IT 852619-30-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 1-(azabicyclic)-4-substituted-imidazoles for use in pharmaceutical compns. as $\alpha 4$ and $\alpha 7$ nicotinic acetylcholine receptor (nAChR) agonists)

RN 852619-30-8 CAPLUS

CN 1-Azabicyclo[2.2.2]octane, 3-[4-(5-bromo-2-thienyl)-1H-imidazol-1-yl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 852619-19-3P 852633-60-4P, (R)-3-(4-Phenylimidazol-1-yl)-1-azabicyclo[2.2.2]octane 852633-62-6P 852633-65-9P
 852633-67-1P 852633-68-2P 852633-70-6P
 852633-72-8P 852633-74-0P 852633-76-2P
 852633-78-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-(azabicyclyl)-4-substituted-imidazoles for use in pharmaceutical compns. as $\alpha 4$ and $\alpha 7$ nicotinic acetylcholine receptor (nAChR) agonists)

RN 852619-19-3 CAPLUS


CN 1-Azabicyclo[2.2.2]octane, 3-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 852633-60-4 CAPLUS

CN 1-Azabicyclo[2.2.2]octane, 3-(4-phenyl-1H-imidazol-1-yl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 852633-62-6 CAPLUS

CN 1-Azabicyclo[2.2.2]octane, 3-[4-[4-(4-morpholinyl)phenyl]-1H-imidazol-1-yl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 852633-65-9 CAPLUS

CN 1-Azabicyclo[2.2.2]octane, 3-[4-(5-phenyl-2-thienyl)-1H-imidazol-1-yl]-, dihydrochloride, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 852633-67-1 CAPLUS
 CN 1-Azabicyclo[2.2.2]octane, 3-[4-(2-thienyl)-1H-imidazol-1-yl]-, (3R)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 852633-68-2 CAPLUS
 CN 1-Azabicyclo[2.2.2]octane, 3-[4-(2-thienyl)-1H-imidazol-1-yl]-, (3R)-,
 bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 852633-67-1
 CMF C14 H17 N3 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2



RN 852633-70-6 CAPLUS
 CN 1-Azabicyclo[2.2.2]octane, 3-(4-[2,2'-bithiophen]-5-yl-1H-imidazol-1-yl)-,

(3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 852633-72-8 CAPLUS

CN 1-Azabicyclo[2.2.2]octane, 3-(4-[2,3'-bithiophen]-5-yl-1H-imidazol-1-yl)-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 852633-74-0 CAPLUS

CN 1-Azabicyclo[2.2.2]octane, 3-[4-[5-(3-furanyl)-2-thienyl]-1H-imidazol-1-yl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 852633-76-2 CAPLUS

CN 1-Azabicyclo[2.2.2]octane, 3-[4-[5-(4-pyridinyl)-2-thienyl]-1H-imidazol-1-yl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 852633-78-4 CAPLUS

CN 1-Azabicyclo[2.2.2]octane, 3-[4-[5-(3-pyridinyl)-2-thienyl]-1H-imidazol-1-yl]-, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2005:472154 CAPLUS
 DOCUMENT NUMBER: 143:7862
 TITLE: Preparation of 1-(azabicyclo[3.3.1]non-2-yl)-5-substituted-imidazoles for use in pharmaceutical compositions as $\alpha 4$ and $\alpha 7$ nicotinic acetylcholine receptor (nAChR) agonists
 INVENTOR(S): Empfield, James; Phillips, Eifion; Throner, Scott
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
 SOURCE: PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049611	A1	20050602	WO 2004-SE1659	20041115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004291456	A1	20050602	AU 2004-291456	20041115
CA 2546093	A1	20050602	CA 2004-2546093	20041115
EP 1687302	A1	20060809	EP 2004-800322	20041115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN 1882583	A	20061220	CN 2004-80034236	20041115
BR 2004016661	A	20070116	BR 2004-16661	20041115
JP 2007511602	T	20070510	JP 2006-541085	20041115
IN 2006DN02419	A	20070420	IN 2006-DN2419	20060501
MX 2006PA05415	A	20060719	MX 2006-PA5415	20060512
NO 2006002868	A	20060821	NO 2006-2868	20060619
PRIORITY APPLN. INFO.:			SE 2003-3076	A 20031119
			WO 2004-SE1659	W 20041115
OTHER SOURCE(S):		CASREACT 143:7862; MARPAT 143:7862		
GI				



AB Azabicyclic-imidazole derivs., such as I [A = azabicyclic, such as 3-quinuclidinyl, or 1-azabicyclo[2.2.1]heptan-3-yl; R1 = aryl, heteroaryl], were prepared for therapeutic use as $\alpha 4$ and $\alpha 7$ nAChR agonists. These imidazoles are claimed for use in the treatment of ulcerative colitis, as well as for use in the treatment or prophylaxis of neurol. disorders, psychotic disorders or intellectual impairment disorders, such as Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, attention deficit hyperactivity disorder, Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapses, jetlag, nicotine addiction, craving, pain, anxiety, schizophrenia, mania or manic depression. Thus, (R)-3-[5-(5-bromothiophen-2-yl)imidazol-1-yl]-1-azabicyclo[2.2.2]octane (II) was prepared via dihydroxylation of 2-acetyl-5-bromothiophene using SeO_2 in H_2O and 1,4-dioxane to form the intermediate glyoxal hydrate, 1-(5-bromothiophen-2-yl)-2,2-dihydroxyethanone, in 73% yield, and subsequent cyclization of the glyoxal hydrate with (R)-(+)-3-aminoquinuclidine dihydrochloride, ammonium acetate and formaldehyde in AcOH and H_2O to give the desired II in 33% yield. The prepared imidazoles were assayed for binding affinity to the $\alpha 4$ and $\alpha 7$ nAChR subtypes using rat hippocampi.


IT 852619-30-8P

RL: BYP (Byproduct); PREP (Preparation)
(preparation of 1-(azabicyclic)-5-substituted-imidazoles for use in pharmaceutical compns. as $\alpha 4$ and $\alpha 7$ nicotinic acetylcholine receptor (nAChR) agonists)

RN 852619-30-8 CAPLUS

CN 1-Azabicyclo[2.2.2]octane, 3-[4-(5-bromo-2-thienyl)-1H-imidazol-1-yl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 852619-19-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1-(azabicyclic)-5-substituted-imidazoles for use in pharmaceutical compns. as $\alpha 4$ and $\alpha 7$ nicotinic acetylcholine receptor (nAChR) agonists)

RN 852619-19-3 CAPLUS

CN 1-Azabicyclo[2.2.2]octane, 3-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 07:57:00 ON 29 AUG 2007)

FILE 'REGISTRY' ENTERED AT 07:57:56 ON 29 AUG 2007

L1	STRUCTURE UPLOADED
L2	STRUCTURE UPLOADED
L3	STRUCTURE UPLOADED
L4	STRUCTURE UPLOADED
L5	13 S L1 FULL
L6	0 S L2 FULL
L7	0 S L3 FULL
L8	0 S L4 FULL

FILE 'CAPLUS' ENTERED AT 08:00:29 ON 29 AUG 2007

L9	2 S L5 FULL
----	-------------

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.48	700.30
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.56	-1.56

STN INTERNATIONAL LOGOFF AT 08:01:49 ON 29 AUG 2007